MX2022003037A - Compuestos antibacterianos. - Google Patents
Compuestos antibacterianos.Info
- Publication number
- MX2022003037A MX2022003037A MX2022003037A MX2022003037A MX2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A MX 2022003037 A MX2022003037 A MX 2022003037A
- Authority
- MX
- Mexico
- Prior art keywords
- antibacterial compounds
- compounds
- tuberculosis
- medicaments
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a los siguientes compuestos (ver Fórmulas) donde los componentes integrantes son como se definen en la descripción, y en donde los compuestos pueden ser útiles como medicamentos, por ejemplo, para su uso en el tratamiento de la tuberculosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197183 | 2019-09-13 | ||
| PCT/EP2020/075458 WO2021048342A1 (en) | 2019-09-13 | 2020-09-11 | Antibacterial compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003037A true MX2022003037A (es) | 2022-04-07 |
Family
ID=67956507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003037A MX2022003037A (es) | 2019-09-13 | 2020-09-11 | Compuestos antibacterianos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220340564A1 (es) |
| EP (1) | EP4028399B1 (es) |
| JP (1) | JP7680433B2 (es) |
| KR (1) | KR20220062564A (es) |
| CN (1) | CN114423758B (es) |
| AU (1) | AU2020346370A1 (es) |
| BR (1) | BR112022003799A2 (es) |
| CA (1) | CA3149868A1 (es) |
| ES (1) | ES2978573T3 (es) |
| MX (1) | MX2022003037A (es) |
| WO (1) | WO2021048342A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| KR20230157400A (ko) * | 2021-03-16 | 2023-11-16 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항박테리아성 화합물 |
| CN118159543A (zh) | 2021-10-28 | 2024-06-07 | 爱尔兰詹森科学公司 | 在治疗细菌感染中使用的咪唑并吡啶酰胺和相关化合物 |
| EP4296674A1 (en) | 2022-06-20 | 2023-12-27 | Université Toulouse III - Paul Sabatier | Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025017047A1 (en) | 2023-07-18 | 2025-01-23 | Janssen Pharmaceutica Nv | Combination products of at least three antibiotics comprising bedaquiline, pretomanid or delamanid, and a cytochrome bc1 inhibitor, and their use in the treatment of mycobacterial infections |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2301544T3 (da) | 2002-07-25 | 2013-01-02 | Janssen Pharmaceutica Nv | Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer |
| AU2011229423B2 (en) | 2010-03-18 | 2015-12-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-infective compounds |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| WO2013033167A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| WO2014015167A2 (en) * | 2012-07-18 | 2014-01-23 | University Of Notre Dame Du Lac | 5,5-heteroaromatic anti-infective compounds |
| DK3027615T3 (da) | 2013-08-02 | 2021-10-25 | Pasteur Institut Korea | Antiinfektionsforbindelser |
| CN105524058B (zh) * | 2014-10-21 | 2018-03-27 | 广州艾格生物科技有限公司 | 吡唑并[1,5‑a]吡啶类化合物及其应用 |
| WO2017001660A1 (en) | 2015-07-02 | 2017-01-05 | Janssen Sciences Ireland Uc | Antibacterial compounds |
| AU2016324598A1 (en) | 2015-09-17 | 2018-03-15 | Marvin J. Miller | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection |
| JP2019518050A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| JP2019518046A (ja) | 2016-06-16 | 2019-06-27 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | 抗菌薬としての複素環式化合物 |
| WO2018084809A1 (en) * | 2016-11-02 | 2018-05-11 | Nanyang Technological University | Methods for the treatment or prevention of mycobacterial infections |
-
2020
- 2020-09-11 WO PCT/EP2020/075458 patent/WO2021048342A1/en not_active Ceased
- 2020-09-11 EP EP20776062.0A patent/EP4028399B1/en active Active
- 2020-09-11 US US17/639,963 patent/US20220340564A1/en active Pending
- 2020-09-11 JP JP2022516117A patent/JP7680433B2/ja active Active
- 2020-09-11 ES ES20776062T patent/ES2978573T3/es active Active
- 2020-09-11 CA CA3149868A patent/CA3149868A1/en active Pending
- 2020-09-11 BR BR112022003799A patent/BR112022003799A2/pt unknown
- 2020-09-11 CN CN202080064727.XA patent/CN114423758B/zh active Active
- 2020-09-11 AU AU2020346370A patent/AU2020346370A1/en active Pending
- 2020-09-11 MX MX2022003037A patent/MX2022003037A/es unknown
- 2020-09-11 KR KR1020227011475A patent/KR20220062564A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7680433B2 (ja) | 2025-05-20 |
| EP4028399C0 (en) | 2024-02-14 |
| EP4028399B1 (en) | 2024-02-14 |
| US20220340564A1 (en) | 2022-10-27 |
| CN114423758B (zh) | 2025-05-27 |
| CA3149868A1 (en) | 2021-03-18 |
| BR112022003799A2 (pt) | 2022-05-24 |
| ES2978573T3 (es) | 2024-09-16 |
| EP4028399A1 (en) | 2022-07-20 |
| KR20220062564A (ko) | 2022-05-17 |
| JP2022548247A (ja) | 2022-11-17 |
| WO2021048342A1 (en) | 2021-03-18 |
| CN114423758A (zh) | 2022-04-29 |
| AU2020346370A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022003037A (es) | Compuestos antibacterianos. | |
| CO2017013408A2 (es) | Compuestos bicíclicos heterocíclicos como agentes antituberculares. | |
| CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| MX2022012313A (es) | Oxisteroles y metodos de uso de los mismos. | |
| UY37201A (es) | Nuevos derivados de pirazolopirimidina | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| CR20170575A (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los continen. | |
| SV2016005257A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| NI201800076A (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
| CL2018000786A1 (es) | Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2016014547A (es) | Compuestos para tratar atrofia muscular espinal. | |
| GT201600091A (es) | Derivados de purina 2, 6-sustituidos y su uso en el tratamiento de trastornos proliferativos | |
| MX2012003101A (es) | Derivados de pirimidina como inhibidores de la proteina tirosina quinasa 2. | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| CL2019003213A1 (es) | Compuestos plaguicidas bicíclicos. | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| MX2018008772A (es) | Formulaciones/composiciones que comprenden un inhibidor de btk. | |
| UY37250A (es) | Derivados macrocíclicos de indol | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| MX2020009022A (es) | Uso de alcoxipirazoles como inhibidores de la nitrificacion. | |
| CO2018011231A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina con afinidad por los receptores canabinoides tipo-2 | |
| UY37443A (es) | Derivados de fenilamina sustituidos en la posición 4 y uso de los mismos para proteger los cultivos combatiendo los microorganismos fitopatógenos no deseados |